Skip to Content

Merck & Co Inc

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Merck Posts Strong Q3 With Broad Portfolio Support, Leading to Slight Fair Value Estimate Increase

Merck reported strong third-quarter results ahead of our projections, and we plan to slightly raise our fair value estimate. Strong and largely broad-based growth supported 14% operational growth excluding COVID-19 sales from Lagevrio. The strong portfolio of branded drugs along with a developing pipeline continues to support Merck’s wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center